



PATENT
ATTORNEY DOCKET NO.: UMDNJ SOM-000-06-13257.00035

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re patent application of:

Robert Ladner et al

Group Art Unit: Not yet Assigned

Serial No.: 09/804700

Examiner: Not yet Assigned

Filing Date: March 13, 2001

For: Uracil DNA Metabolism as a Target for
Chemotherapy: Screening Assays and Related
Methods

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.8(a)

I hereby certify that this paper, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date indicated below, with sufficient postage, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231

BY:

DATE:

Commissioner for Patents
Washington, D.C. 20231
Sir:

INFORMATION DISCLOSURE STATEMENT


Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

- (x) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

- () In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with () the first or () second After Final Submission, therefore:
- () Certification in Accordance with §1.97(e) is attached; or
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:
- () Certification in Accordance with §1.97(e) is attached; or
- () The fee of \$240.00 as set forth in §1.17(p) is attached.
- () In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).
- (x) Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- () Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- () In view of the voluminous nature of references **[list as appropriate]**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
- () In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:
- () Copies of references **[list as appropriate]** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. , filed .
- () If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1089. This form is submitted in duplicate.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Janet E. Reed", is written over a horizontal line.

Janet E. Reed, Ph.D.

Registration No. 36,252

SAUL EWING LLP
Centre Square West
1500 Market Street, 38th Floor
Philadelphia, PA 19102
Phone: 215-972-8386
Fax: 215-972-2292